Therefore, this study aimed to investigate whether increased CSF p-tau is related to amyloid pathology, tau pathology, or both, and whether CSF Aβ42 can be decreased in the absence of amyloid pathology in certain disease pathologies. The gene discussed is MAPT; the disease is amyloidosis.